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Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that
BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared
survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We
obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation
and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for
men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (Po0.01). It may be
important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
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BRCA2 is a multisite cancer gene. It is generally thought that
BRCA2 mutations primarily affect women, but men with mutations
are also at elevated cancer risk. The two most important cancer
sites for males who carry a mutation are the prostate and the
pancreas (Liede et al, 2004). The risk of prostate cancer is elevated
approximately fivefold in BRCA2 carriers, compared to non-
carriers. Genetic counselors and urologists advise men with BRCA2
mutations to undergo surveillance with annual PSA testing from
the age of 40 years – a recommendation based on the perceived
effectiveness of prostate screening. It is hoped that screening leads
to early diagnosis, when cure rates are high. A recent study from
Iceland suggests that prostate cancers in men with a BRCA2
mutation may be unusually aggressive (Tryggvadottir et al, 2007).
Tryggvadottir et al (2007) identified the Icelandic founder
mutation (BRCA2 999 del5) in 30 of the 527 prostate cancer
patients studied (5.7%). Men with a BRCA2 mutation had a median
survival of only 2.1 years, compared with 12.4 years for noncarriers
(Po0.01). The survival difference could not be explained by stage
or grade. It is important that these findings be replicated because
of the implications for the screening of men with a BRCA2
mutation. We identified the prostate cancer patients in a panel of
2673 families with a BRCA1 or a BRCA2 mutation and estimated
survival of the men in the two subgroups.
METHODS
Men with prostate cancer were included in the survival analysis if
they were from a family with a BRCA mutation and if they were (a)
known to carry the familial BRCA mutation, or (b) if they were a
first-degree relative of a known carrier, or (c) if they were a first-
degree relative of a woman diagnosed with breast or ovarian
cancer. For each eligible man with prostate cancer, information
was collected on age at diagnosis, age at death (if deceased) or age
when last known alive (if alive). Information was collected by the
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review of the family pedigree and the medical record of the
proband. In some cases, this was supplemented by the interview of
another family member. Men who had been diagnosed with other
forms of cancer were excluded.
We identified 938 families with a BRCA2 mutation in the
database. These families came from 33 different clinical centres in
five countries. Of these, 277 families contained one or more cases
of prostate cancer (29.5%). In aggregate, the 277 families included
434 men with prostate cancer (mean 1.6 per family). In all 141 of
the cases were ineligible (either known to be a noncarrier, married
in, not closely related to a carrier or an affected woman or had a
history of cancer other than prostate). Of the remaining 293
prostate cancer patients, we obtained data on age at diagnosis and
age at death (or current age if alive) on 183 (62%). Of these, 67
were determined to carry the familial BRCA2 mutation and 116
men were probable mutation carriers.
Men from families with BRCA1 mutations were selected as the
comparison group. To ensure comparability, we used the same
inclusion criteria as were used for the BRCA2 carriers. We
identified 1735 families with a BRCA1 mutation, of which 316
families contained one or more cases of prostate cancer (18.2%).
The 316 families included 457 men with prostate cancer (a mean of
1.4 per family). A total of 252 of the cases were ineligible (either
known to be a noncarrier, married in, not closely related to a
carrier or an affected woman or had a history of cancer other than
prostate); of the remaining 205 patients, we had data on age at
diagnosis and age at death (or current age if alive) on 119 men
(58%). Of these, 37 were determined to carry the familial BRCA1
mutation and 82 men were likely to be a carrier.
We performed survival analysis to establish the overall survival
of BRCA2 mutation carriers with prostate cancer and the relative
survival as compared to BRCA1 carriers. Patients were followed
from the year of diagnosis until year of death (if deceased) or year
when last known alive (in most cases 2007). Kaplan–Meier
methods were used to construct survival curves, and the
significance of the comparison of the curves was based on the
log-rank test. A hazard ratio was estimated using the Cox
proportional hazards model implemented in SAS version 9.1.3
version The hazard ratio was adjusted for age of diagnosis.
RESULTS
There were 183 men with prostate cancer who were known or
probable carriers of a BRCA2 mutation and 119 men with prostate
cancer who were known or probable carriers of a BRCA1 mutation.
The average age of diagnosis was similar for men in the two groups
(Table 1). The median survival time was 8.0 years for BRCA1
carriers (or probable carriers) and was 4.0 years for BRCA2
carriers (or probable carriers) (Figure 1). The 5-year overall
survival was 57% for BRCA1 carriers and was 39% for BRCA2
carriers. The 10-year survival was 47% for BRCA1 carriers and 25%
for BRCA2 carriers. The 15-year overall survival was 35% for
BRCA1 carriers and 12% for BRCA2 carriers. We estimated the
hazard ratio for all-cause mortality for BRCA2 vs BRCA1 carriers,
adjusted for age, over the entire follow-up period. We found that
the risk of dying in cases from BRCA2 families was 70% higher
than in cases from BRCA1 families (HR¼ 1.7; 95% CI 1.2–2.4)
(Table 2).
The analysis was then repeated, including only known carriers
(67 BRCA2 and 37 BRCA1). The median survival time was 15 years
for carriers of a BRCA1 mutation and was 5.0 years for carriers of a
BRCA2 mutation (Figure 2). The 5-year overall survival was 64%
for BRCA1 carriers and 42% for BRCA2 carriers. The 10-year
survival was 60% for BRCA1 carriers and 26% for BRCA2 carriers.
The 15-year overall survival was 50% for BRCA1 carriers and 4%
for BRCA2 carriers. We estimated the hazard ratio for all-cause
mortality for BRCA2 vs BRCA1 carriers, adjusted for age, over the
entire follow-up period. The hazard ratio was 2.5 (95% CI 1.3–4.7;
P¼ 0.005).
DISCUSSION
In this study, we examined survival for men with prostate cancer
and a BRCA2 mutation, and compared this to a similar group of
men with a BRCA1 mutation. Prostate cancer is a clinical
Table 1 Characteristics of study subjects
BRCA1 BRCA2
Variables
N¼ 119 (37
known carriers)
N¼ 183 (67
known carriers) P
Age at diagnosis (range)
All subjects 66.9 (41–86) 67.1 (32–97) 0.87
Known carriers 70.2 (55–86) 67.1 (49–84) 0.08
Vital status N (%)
All subjects
Alive 72 (60.5) 67 (36.6)
Dead 47 (39.5) 116 (63.4) o0.0001
Known carriers
Alive 24 (64.9) 24 (35.8)
Dead 13 (35.1) 43 (64.2) 0.004
Mean follow-up years (range)
All subjects 4.3 (0–15) 4.1 (0–15) 0.74
Known carriers 5.7 (0–15) 4.3 (0–10) 0.14
P-values calculated for mean using Student’s t-test, and for frequencies using w2 test.
Table 2 All cause mortality in BRCA2 vs BRCA1 patients with prostate
cancer
Univariate Age-adjusted
HR (95% CI) P HR (95% CI) P
BRCA2 vs BRCA1
All subjects
1.64 (1.17–2.30) 0.005 1.71 (1.22–2.41) 0.002
BRCA2 vs BRCA1
Known carriers
2.41 (1.28–4.52) 0.006 2.48 (1.31–4.70) 0.005
Hazard ratio represents mortality experience of patients with BRCA2 mutations
compared to those with BRCA1 mutations, calculated using Cox proportional
hazards model.
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Figure 1 Probability of survival after prostate cancer in men from
families with BRCA1 and BRCA2 mutations (all causes of death).
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manifestation of the BRCA2 gene, but only a small proportion of
prostate cancers are attributable to BRCA2 mutations. An excess
risk of prostate cancer among men with BRCA2 mutations has
been previously documented. Epidemiology studies have been of
two types: (1) estimating the risk of prostate cancer in men from
families with BRCA2 mutations, and (2) estimating the proportion
of BRCA2 mutations among unselected men with prostate cancer.
In a study of 173 families with BRCA2 mutations, the Breast Cancer
Linkage Consortium reported in 1999 that there was a significantly
increased risk of prostate cancer among male first-degree relatives
of female carriers (Breast Cancer Linkage Consortium, 1999). They
estimated the odds ratio to be 4.7 (95% CI 3.5– 56.2). In a study in
the Netherlands of 139 families with BRCA2 mutations, Van
Asperen et al (2005) confirmed an excess risk of prostate cancer in
first-degree relatives of carriers (OR¼ 2.5; 95% CI 1.6–3.8). Given
that only one-half of the first-degree relatives are expected to be
gene carriers, this corresponds to a relative risk of prostate cancer,
given a BRCA2 mutation, of approximately five.
Kirchoff et al (2004) tested 251 unselected Ashkenazi Jewish
men with prostate cancer from the New York area for the two
founder mutations in BRCA1 and the one in BRCA2. They also
tested 1472 Ashkenazi controls. A mutation was found in 5.2% of
cases and 1.9% of controls. The presence of a BRCA2 mutation was
associated with a 4.8-fold increased risk of prostate cancer. In
contrast, the BRCA1 carriers in that study were not at increased
risk of prostate cancer. In a study from the United States, Agalliu
et al (2007) found a BRCA2 mutation in two of 290 men diagnosed
with prostate cancer under the age of 55 (mixed ethnicities). The
relative risk for early-onset prostate cancer was 7.8.
We observed that men with prostate cancer and a BRCA2
mutation experienced relatively poor survival, in comparison to
men with prostate cancer and a BRCA1 mutation. The median
survival for BRCA2 carriers was 4.0 years, and at 10 years
post-diagnosis, 53% of the patients had died.
There are several limitations to our study. Ideally, one would
follow a cohort of unselected patients with prostate cancer and a
BRCA2 mutation, record details on the stage, grade and all
treatments received, and then compare the outcome of the
hereditary group with a similar group of patients without a
mutation. We do not know the cause of death for these patients
and expect that some will have died of causes other than prostate
cancer. Not all of the patients in our study were proven carriers of
a BRCA2 mutation; we included 67 carriers (or obligate carriers)
and 116 men with prostate cancer who had not been tested for the
presence of the mutation. The families in this study were those
referred to various cancer genetics centres because of multiple
cases of breast and/or ovarian cancer in the family, and were not
selected on the basis of prostate cancer. The demographic and
clinical information on the patients with prostate cancer were
taken from a pedigree review and interview of the proband; we did
not review the medical record or the pathology report of the
prostate cancer patient. The ages of diagnosis and death were
based on information provided by the female proband. It may be
probable that not all cases of prostate cancer in male relatives were
recorded. We do not know if the case was diagnosed clinically or
through prostate cancer screening. We do not have information on
the stage or grade at presentation, and we did not record details of
treatment.
Despite these numerous limitations, we believe that the
differences observed in survival of the BRCA1 and BRCA2 carriers
(Figures 1 and 2) can be attributed to the adverse effect of the
BRCA2 mutation on prostate cancer survival. These data were
recorded and collected using the same methods for the BRCA1 and
BRCA2 families. There is no reason to believe that carriers of
BRCA2 mutations should have greater mortality than men with
BRCA1 mutations from non-cancer causes, and men with other
forms of cancer were excluded. The survival experience of the
BRCA2 carriers is almost universally poor, as only 26% of the
known carriers were alive 10 years after diagnosis and 4% were
alive at 15 years. Compared to men with a BRCA1 mutation, men
with a BRCA2 mutation in this study were more than two times as
likely to die (of any cause) following the diagnosis of prostate
cancer (hazard ratio 2.5), and it is likely that the relative mortality
for prostate cancer-specific mortality would be even more extreme.
These data support the conclusions of Tryggvadottir et al (2007)
who reported that men with prostate cancer and a BRCA2
mutation experienced an unexpectedly high rate of mortality.
The basis for the aggressive behaviour of the BRCA2-associated
prostate cancers is not known. Moro et al (2008) show that
downregulation of BRCA2 expression through the introduction of
siRNA in prostate cancer cells promoted cancer cell migration and
invasion. Mitra et al (2008) found the average grade of prostate
cancers among men with BRCA2-associated prostate cancers
(Gleason score) to be higher than that of noncarrier control
tumours.
We compared the survival of men with BRCA2 mutations with
that of men with BRCA1 mutations. Ideally, we would have
included a comparison group of noncarriers as well. However, it
was not possible to identify a similar group of noncarrier patients
from this database, given that we routinely collect pedigree
information only on families with a mutation in one of the two
genes. Although we do not have a comparable group of noncarriers
in this study, it has been reported in a trial of patients undergoing
watchful waiting vs prostatectomy that 27% of men with
prostatectomy died within 10 years of diagnosis (all-cause
mortality) and 32% of men with watchful waiting died within 10
years of diagnosis (Bill-Axelson et al, 2005). In comparison, 75% of
the BRCA2 carriers in our study died within 10 years of diagnosis.
If survival in BRCA1 carriers is atypical, then our observed
difference will not be representative of prostate cancer in general.
To our knowledge, BRCA1 is not associated with an improved
survival experience. Furthermore, the risk of prostate cancer in
BRCA1 carriers is increased only to a small extent, if any (Kirchoff
et al, 2004; Cybulski et al, 2008), and an increased risk is not
associated with all mutations (Cybulski et al, 2008). Therefore, we
expect the survival experience of men with prostate cancer in
BRCA1 families to be similar to that of the general population.
The data from the two studies suggest that men with BRCA2
mutations may not benefit from current therapies to the same
extent as other men. We do not know which men in this cohort
had screen-detected prostate cancer, and it will be important to
study whether or not men who have subclinical, screen-detected
prostate cancer also experience a high mortality rate. To address
this issue, we plan to identify the BRCA2 carriers among a large
sample of prostate cancer patients and to characterise them in
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Figure 2 Probability of survival after prostate cancer in known carriers
with BRCA1 and BRCA2 (all causes of death).
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terms of clinical presentation, pathology and response to
treatment. Future studies should also address whether current
surgical and non-surgical treatments improve survival from
prostate cancer among BRCA2 carriers. Current treatments include
surgery, hormonal-based therapies and radiotherapy. Given that
the BRCA2 protein is involved in the repair of damaged DNA
breaks, and that radiation induces double-strand breaks, it is
possible that prostate cancer patients with a BRCA2 mutation are
more sensitive to radiotherapy than patients without a mutation.
Cytotoxic chemotherapy is not generally used in the early
treatment of prostate cancer. Currently, there is interest in
identifying directed treatments for breast cancer in BRCA1 and
BRCA2 carriers. Drugs that induce DNA-strand breaks, such as
cis-platinum, show increased sensitivity in pre-clinical models,
and trials are now underway to study cis-platinum and PARP1
inhibitors in women with breast cancer and a BRCA mutation. A
male patient with metastatic prostate cancer and a BRCA2
mutation has responded well to a PARP1 inhibitor (A Tutt, J De
Bono, personal communication). It will be a matter of considerable
interest to see whether or not the men with prostate cancer and a
BRCA2 mutation benefit from targeted chemotherapy.
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